Friday, June 13
14.00-17.00  Yellow Hall

> Welcome and introduction
G. Mancia (Monza, Italy)

> Total risk assessment: where are we now?
G. De Backer (Ghent, Belgium)

> Mechanisms of stroke: benefits in lipid lowering
J. Kastelein (Amsterdam, The Netherlands)

> Mechanisms of stroke: benefits in blood pressure reduction
J. Staessen (Leuven, Belgium)

> Cholesterol-lowering trials in their epidemiological context
R. Collins (Oxford, UK)

> Antihypertensive treatment: impact of meta-analyses
S. MacMahon (Sydney, Australia)

> Panel discussion

> ALLHAT: what has it taught us, and what is still missing?
F. Leenen (Ottawa, Canada)

> ASCOT: implications for the management of hypertension and hyperlipidemia
P. Sever (London, UK)

> Panel discussion and closing remarks
B. Dahlöf (Göteborg, Sweden)